Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Discovery: Overview01:26

Drug Discovery: Overview

12.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.5K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

56
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
56
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

71
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
71
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

614
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
614
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

429
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
429
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.4K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Population Pharmacokinetic Model-Based Dose Selection of Extended-Release Injectable Olanzapine (TV-44749) for Subcutaneous Use in Phase 3 Clinical Trial in Adults with Schizophrenia.

Journal of clinical pharmacology·2026
Same author

AI-NLME: A New Artificial Intelligence-Driven Nonlinear Mixed Effect Modeling Approach for Analyzing Longitudinal Data in Randomized Placebo-Controlled Clinical Trials.

Clinical and translational science·2025
Same author

A novel artificial intelligence-based methodology to predict non-specific response to treatment.

Psychiatry research·2025
Same author

Comparison of Different Machine Learning Methodologies for Predicting the Non-Specific Treatment Response in Placebo Controlled Major Depressive Disorder Clinical Trials.

Clinical and translational science·2025
Same author

Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses to treatment.

Journal of pharmacokinetics and pharmacodynamics·2024
Same author

Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease.

Journal of pharmacokinetics and pharmacodynamics·2024

相关实验视频

Updated: Mar 7, 2026

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

1.7K

深度学习与基于模型的药物开发中的假设驱动建模:PK/PD案例研究

Roberto Gomeni1, Françoise Bressolle-Gomeni1

  • 1R&D Department, PharmacoMetrica, Lieu-dit Longcol, La Fouillade, France.

Journal of clinical pharmacology
|March 6, 2026
PubMed
概括
此摘要是机器生成的。

这项研究比较了药物开发中的深度学习和基于假设的建模. 整合这两种方法可以增强基于模型的药物开发 (MIDD),从而提高决策能力.

关键词:
人工智能的人工智能是人工智能.深度学习是一种深度学习.选择剂量选择剂量选择这是一个由假设驱动的假设.基于模型的药物开发信息.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.5K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K

相关实验视频

Last Updated: Mar 7, 2026

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

1.7K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.5K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K

科学领域:

  • 药理学和药物开发领域
  • 计算生物学 计算生物学
  • 人工智能在医学中的应用

背景情况:

  • 基于模型的药物开发 (MIDD) 传统上依赖于假设驱动的建模.
  • 新兴的人工智能 (AI) 能够实现数据驱动的建模,通常没有明确的机械假设.
  • 这些范式之间的协同作用正在改变MIDD战略.

研究的目的:

  • 在MIDD中比较基于深度学习和基于假设的建模方法.
  • 突出每个范式的优势,局限性和整合机会.
  • 使用这两种方法重新分析华法林的药理动力学 (PK) 和药理动力学 (PK/PD).

主要方法:

  • 对华法林PK的深度学习和假设驱动模型的比较分析.
  • 评估PK/PD模型 (直接效应,效应区,间接响应) 与深度学习方法相比.
  • 基于模拟的灵敏度分析用于深度学习模型的稳定性.

主要成果:

  • 深度学习的PK模型的性能是可比的,在数值上略高于一个单间假设驱动的模型.
  • 深度学习PK/PD模型的性能与效应区和间接响应模型相似.
  • 这两种方法都产生了对华法林有效剂量的可比估计值.

结论:

  • 深度学习和假设驱动模型的互补使用可以增强MIDD.
  • 整合支持基于证据的药物开发和监管决策.
  • 将人工智能与机械洞察力结合起来,可以优化药物开发策略.